why TherapeuticsMD Inc. [TXMD] is a Good Choice for Investors After New Price Target of $4.33

Related

TherapeuticsMD Inc. [NASDAQ: TXMD] slipped around -0.01 points on Friday, while shares priced at $0.36 at the close of the session, down -3.58%. The company report on December 10, 2021 that U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA®.

– FDA determined that it could not approve proposed revisions to the manufacturing testing limits requested through the Supplemental New Drug Application (sNDA) — FDA provided recommendations and requested additional information to address the issues — The Company will continue to supply ANNOVERA in compliance with the manufacturing testing limits approved in the original NDA -.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


TherapeuticsMD, Inc. (NASDAQ:TXMD) (“TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that the FDA determined that it could not approve revisions to certain manufacturing testing limits for ANNOVERA through the sNDA previously submitted by the Company. In its complete response letter, the FDA provided recommendations and requested additional information that could support approval of revisions to certain manufacturing testing limits. The Company will continue to manufacture and supply ANNOVERA under the existing approved specifications.

TherapeuticsMD Inc. stock is now -70.62% down from its year-to-date (YTD) trading value. TXMD Stock saw the intraday high of $0.3775 and lowest of $0.3515 per share. The company’s 52-week high price is 2.75, which means current price is +1.14% above from all time high which was touched on 02/09/21.

Compared to the average trading volume of 4.77M shares, TXMD reached a trading volume of 7537643 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about TherapeuticsMD Inc. [TXMD]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TXMD shares is $4.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TXMD stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Jefferies have made an estimate for TherapeuticsMD Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on August 07, 2020. The new note on the price target was released on May 19, 2020, representing the official price target for TherapeuticsMD Inc. stock.

The Average True Range (ATR) for TherapeuticsMD Inc. is set at 0.04, with the Price to Sales ratio for TXMD stock in the period of the last 12 months amounting to 1.70.

How has TXMD stock performed recently?

TherapeuticsMD Inc. [TXMD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -12.24. With this latest performance, TXMD shares dropped by -22.28% in over the last four-week period, additionally sinking by -68.26% over the last 6 months – not to mention a drop of -70.62% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TXMD stock in for the last two-week period is set at 29.42, with the RSI for the last a single of trading hit 25.83, and the three-weeks RSI is set at 31.29 for TherapeuticsMD Inc. [TXMD]. The present Moving Average for the last 50 days of trading for this stock 0.5629, while it was recorded at 0.3781 for the last single week of trading, and 0.9208 for the last 200 days.

TherapeuticsMD Inc. [TXMD]: Deeper insight into the fundamentals

TherapeuticsMD Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.80 and a Current Ratio set at 1.90.

Earnings analysis for TherapeuticsMD Inc. [TXMD]

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TXMD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for TherapeuticsMD Inc. go to 17.60%.

>> 7 Top Picks for the Post-Pandemic Economy <<

Insider trade positions for TherapeuticsMD Inc. [TXMD]

There are presently around $47 million, or 37.10% of TXMD stock, in the hands of institutional investors. The top three institutional holders of TXMD stocks are: BLACKROCK INC. with ownership of 25,306,542, which is approximately 1.878% of the company’s market cap and around 0.80% of the total institutional ownership; VANGUARD GROUP INC, holding 18,910,787 shares of the stock with an approximate value of $6.71 million in TXMD stocks shares; and FMR LLC, currently with $4.95 million in TXMD stock with ownership of nearly 0.357% of the company’s market capitalization.

72 institutional holders increased their position in TherapeuticsMD Inc. [NASDAQ:TXMD] by around 11,731,734 shares. Additionally, 58 investors decreased positions by around 47,168,464 shares, while 44 investors held positions by with 74,250,060 shares. The mentioned changes placed institutional holdings at 133,150,258 shares, according to the latest SEC report filing. TXMD stock had 21 new institutional investments in for a total of 3,914,474 shares, while 23 institutional investors sold positions of 19,274,462 shares during the same period.